Podcast: Biotech CEO Interview – Harbour BioMed's Wang On Moderna Deal, New Subsidiary
Enable "ideas to IND", shift from China to global
After inking major deals with AbbVie and AstraZeneca, China-US company Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” and emerge stronger post-pandemic, says founder, chairman and CEO Jingsong Wang in an exclusive interview.
